CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

Author(s):

Richard Isaacson, MD,Sharon Cohen, MD, FRCPC

Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.

EP: 1.Apolipoprotein E4 in Alzheimer’s Disease

EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease

EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease

EP: 5.Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

EP: 6.Utilization of Neuroimaging in Alzheimer’s Disease

Now Viewing

EP: 7.CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

EP: 8.Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

EP: 9.Alzheimer’s Disease Pipeline

EP: 10.The Future Outlook for Alzheimer’s Disease

Video content above is prompted by the following questions:

Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
  - What are the unmet needs?